Are There Shortages and Regional Disparities in Lecanemab Treatment Facilities? A Cross-Sectional Study
Introduction: Alzheimer disease (AD) is the most common type of dementia, affecting 70% of patients with dementia. In Japan, over 5 million people aged 65 years and older had dementia in 2018, and this figure is expected to rise to 25% to 30% of this age group by 2045. In Japan, lecanemab, which was...
Saved in:
Main Authors: | Kazuki Ohashi (Author), Ikuko Takahashi-Iwata (Author), Zhao Jieyu (Author), Ken Sakushima (Author), Ichiro Yabe (Author), Katsuhiko Ogasawara (Author) |
---|---|
Format: | Book |
Published: |
SAGE Publishing,
2024-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer's Disease
by: Connie Yoon, et al.
Published: (2024) -
The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint
by: Linus Jönsson, et al.
Published: (2023) -
Optimal allocation of physicians improves accessibility and workload disparities in stroke care
by: Kazuki Ohashi, et al.
Published: (2023) -
Aducanumab and lecanemab - two novel antibodies against pathologic species of amyloid beta in the treatment of Alzheimer's disease
by: Jakub Wojcieszak
Published: (2023) -
The Capacitated Maximal Covering Location Problem Improves Access to Stroke Treatment: A Cross-Sectional Simulation Study
by: Kyohei Bando, et al.
Published: (2024)